Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism

Journal of Cellular Physiology

Volumn 220, Issue 3, 2009, Pages 655-663

  Czekay, Ralf Peter ^a   Loskutoff, David J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEASE NEXIN I; UROKINASE; UROKINASE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5; ALPHA3 INTEGRIN; AMYLOID PRECURSOR PROTEIN; CELL SURFACE RECEPTOR; FIBRONECTIN; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE NEXINS; RECOMBINANT PROTEIN; VITRONECTIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL ADHESION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME INACTIVATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION; CELL LINE, TUMOR; ENDOCYTOSIS; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; INTEGRIN ALPHA3; MICE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; TRANSFECTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 67650403484     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21806     Document Type: Article

References (52)

1. Aguirre Ghiso JA, Kovalski K, Ossowski L. 1999. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:103.
2. Andreasen PA, Egelund R, Petersen HH. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40.
3. Bass R, Ellis V. 2009. Regulation of urokinase receptor function and pericellular proteolysis by the integrin α5β1. Thromb Haemost 101:954-962.
4. Berkenpas MB, Lawrence DA, Ginsburg D. 1995. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14:2969-2977.
5. Carriero MV, Franco P, Vocca I, Alfano D, Votta G, Longanesi-Cattani I, Bifulco K, Mancini A, Caputi M, Stoppelli MP. 2009. Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci 14:3782-3794.
6. Chapman HA, Wei Y. 2001. Protease crosstalk with integrins: The urokinase receptor paradigm. Thromb Haemost 86:124-129.
7. Conese M, Blasi F. 1995. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe Seyler 376:143-155.
8. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F. 1989. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 86:4828-4832.
9. Czekay R-P, Loskutoff DJ. 2004. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med 229:1090-1096.
10. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. 2001. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 12:1467-1479.
11. Czekay R-P, Aertgeerts K, Curriden SA, Loskutoff DJ. 2003. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791.
12. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571.
13. Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33.
14. Eddy AA. 2009. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 101:656-664.
15. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. 2000. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60:636-643.
16. Goldfinger LE, Stack MS, Jones JC. 1998. Processing of laminin-5 and its functional consequences: Role of plasmin and tissue-type plasminogen activator. J Cell Biol 141:255-265.
17. Heegaard CW, Simonsen ACW, Oka K, Kjoller L, Christensen A, Madsen B, Ellgaard L, Chan L, Andreasen PA. 1995. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 270:20855-20861.
18. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 1991. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 266:21232-21238.
19. Kamikubo Y, Okumura Y, Loskutoff DJ. 2002. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem 277:27109-27119.
20. Kjoller L. 2002. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 383:5-19.
21. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232:420-429.
22. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T. 1994. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71:474-480.
23. Laura R, Robison DJ, Bing DH. 1980. (p-Amidinophenyl)methanesulfonyl fluoride, an irreversible inhibitor of serine proteases. Biochemistry 19:4859-4864.
24. Lauffenburger DA, Horwitz AF. 1996. Cell migration: A physically integrated molecular process. Cell 84:359-369.
25. Mondino A, Resnati M, Blasi F. 1999. Structure and function of the urokinase receptor. Thromb Haemost 82:19-22.
26. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, Weber MJ, Gonias SL. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 146:149-164.
27. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. 2000. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 275:19382-19388.
28. Nykjær A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. 1997. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 16:2610-2620.
29. Okumura Y, Kamikubo Y, Curriden SA, Wang J, Kiwada T, Futaki S, Kitagawa K, Loskutoff DJ. 2002. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 277:9395-9404.
30. Ossowski L, Aguirre-Ghiso JA. 2000. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613-620.
31. Palmieri D, Lee JW, Juliano RL, Church FC. 2002. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 Breast Cancer Cells. J Biol Chem 277:40950-40957.
32. Powelka AM, Sun J, Li J, Gao M, Shaw LM, Sonnenberg A, Hsu VW. 2004. Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11. Traffic 5:20-36.
33. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM, Stockinger H, Binder BR. 2004. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 94:1562-1570.
34. Ramos JW, DeSimone DW. 1996. Xenopus embryonic cell adhesion to fibronectin: Position-specific activation of RGD/synergy site-dependent migratory behavior at gastrulation. J Cell Biol 134:227-240.
35. Seiffert D, Ciambrone G, Wagner NV, Binder BB, Loskutoff DJ. 1994. The somatomedin B domain of vitronectin: Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269:2659-2666.
36. 3 binding to vitronectin. Nature 383:441-443.
37. Stefansson S, Lawrence DA. 2003. Old dogs and new tricks, proteases, inhibitors, and cell migration. Sci STKE 189:pe24.
38. Stefansson S, Muhammad S, Cheng X-F, Battey FD, Strickland DK, Lawrence DA. 1998. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 273:6358-6366.
39. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. 1998. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273:18268-18272.
40. Tarui T, Mazar AP, Cines DB, Takada Y. 2001. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 276:3983-3990.
41. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. 1997. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100:58-67.
42. Wang M, Loewik DW, Miller AD, Thanou M. 2009. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. Bioconjugat Chem 20:32-40.
43. Wang Y, Liang X, Wu S, Murrell GA, Doe WF. 2001. Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 92:257-262.
44. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388.
45. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. 2001. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol Biol Cell 12:2975-2986.
46. Wei Y, Czekay R-P, Robillard L, Kugler MC, Zhang F, Kim KK, Xiong JP, Humphries MJ, Chapman HA. 2005. Regulation of a5b1 integrin conformation and function by urokinase receptor binding. J Cell Biol 168:501-511.
47. Woods AJ, White DP, Caswell PT, Norman JC. 2004. PKD1/PKC micro promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions. EMBO J 23:2531-2543.
48. Xiong JP, Stehle T, Goodman SL, Arnaout MA. 2003. Integrins, cations and ligands: Making the connection. J Thromb Haemost 1:1642-1654.
49. Xue W, Mizukami I, Todd RF III, Petty HR. 1997. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 57:1682-1689.
50. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. 1988. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 13:281-292.
51. Yebra M, Goretzki L, Pfeifer M, Mueller BM. 1999. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250:231-240.
52. Zhang F, Tom CC, Kugler MC, Ching TT, Kreidberg JA, Wei Y, Chapman HA. 2003. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J Cell Biol 163:177-188.